Investing.com -- On Sunday, April 11, 2025, GeoVax, Inc. was instructed by Advanced Technology International (ATI) to cease all work related to a specific project agreement. The project, identified as Agreement No. 01; RRPV-24-04-NGVx-006, was titled "NextGen Vaccinations: Phase 2B Clinical Trial Execution: Phase 2b study to evaluate GEO-CM04S1 COVID-19 vaccine" and was part of the Consortium Base Agreement No. 2024-564.

ATI oversees the Rapid Response Partnership Vehicle’s Consortium Management Firm, which is financially supported by the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services. The written notice from ATI indicated that BARDA had opted to end the contract at their discretion, as allowed by the terms of the Project Agreement.

This information was disclosed via an SEC filing by GeoVax, Inc. The reasons behind BARDA’s decision to terminate the contract have not been detailed in the notice. As of now, no further information regarding the future of the project or its impact on GeoVax’s operations has been provided.

GeoVax stock fell 13.1% in after-hours trading following the announcement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.